Zeng Wanting, Zhu Wei, Yuan Guosheng, Chen Jinzhang, Wang Zhanhui, Hou Jinlin, Jiang De-Ke
State Key Laboratory of Organ Failure Research, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Hepatology, Guangdong Provincial Research Center for Liver Fibrosis Engineering and Technology, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Cancer Immunol Immunother. 2025 Jul 1;74(8):257. doi: 10.1007/s00262-025-04122-z.
Hepatocellular carcinoma (HCC) ranks among the most prevalent malignant tumors globally. However, current frontline treatment modalities fail to achieve satisfactory therapeutic outcomes. In recent years, T-cell receptor (TCR)-T therapy has garnered increasing attention as a promising therapeutic approach. This review provides an overview of the epidemiology of HCC, evaluates the efficacy of current first-line treatment options, and introduces adoptive cellular therapies (ACTs), with a specific focus on TCR-T therapy. Notably, we categorize existing TCR-T research targeting different antigens for the treatment of HCC, covering both published literature and registered clinical trials. Furthermore, we discuss the limitations of current TCR-T research and applications, while offering insights into future research directions and development prospects. In summary, this review comprehensively examines the research progress on TCR-T therapy for HCC from the perspective of antigen targeting. Although several challenges remain to be addressed, we believe that TCR-T therapy represents a promising approach for the treatment of HCC.
肝细胞癌（HCC）是全球最常见的恶性肿瘤之一。然而，目前的一线治疗方式未能取得令人满意的治疗效果。近年来，T细胞受体（TCR）-T疗法作为一种有前景的治疗方法受到越来越多的关注。本综述概述了HCC的流行病学，评估了当前一线治疗方案的疗效，并介绍了过继性细胞疗法（ACTs），特别关注TCR-T疗法。值得注意的是，我们对现有的针对不同抗原治疗HCC的TCR-T研究进行了分类，涵盖已发表的文献和注册的临床试验。此外，我们讨论了当前TCR-T研究和应用的局限性，同时对未来的研究方向和发展前景提供了见解。总之，本综述从抗原靶向的角度全面审视了TCR-T疗法治疗HCC的研究进展。尽管仍有一些挑战有待解决，但我们相信TCR-T疗法是治疗HCC的一种有前景的方法。
